We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+0.75%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$1.31B
AUM Growth
+$305M
Cap. Flow
+$326M
Cap. Flow %
24.94%
Top 10 Hldgs %
40.19%
Holding
87
New
20
Increased
35
Reduced
4
Closed
23

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$37.6M
2
SGI
Somnigroup International
SGI
+$37.3M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$32.2M
4
PRKS icon
United Parks & Resorts
PRKS
+$29.4M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$27.3M

Top Sells

Rank Stock Value
1
ENR icon
Energizer
ENR
+$29.4M
2
CMG icon
Chipotle Mexican Grill
CMG
+$22.5M
3
GSK icon
GSK
GSK
+$14.6M
4
GME icon
GameStop
GME
+$14.4M
5
BJRI icon
BJ's Restaurants
BJRI
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 46.43%
2 Consumer Discretionary 25.02%
3 Miscellaneous 18.11%
4 Consumer Staples 9.24%
5 Financials 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
26
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$21.9M 1.67%
1,540,000
+540,000
+54% +$7.98M
TLRD
27
DELISTED
Tailored Brands, Inc.
TLRD
$20M 1.53%
800,000
+20,000
+3% +$463K
GAP
28
The Gap Inc
GAP
$7.86B
$20M 1.53%
640,000
+240,000
+60% +$7.85M
DESP
29
DELISTED
Despegar.com
DESP
$19M 1.45%
+608,000
New +$18.1M
CPRI icon
30
Capri Holdings
CPRI
$1.49B
$18.6M 1.42%
300,000
+64,000
+27% +$4.07M
PGNX
31
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$17.9M 1.37%
+2,400,000
New +$16M
TSCO icon
32
Tractor Supply
TSCO
$18.3B
$17.3M 1.33%
+1,375,000
New +$19.2M
ACHN
33
DELISTED
Achillion Pharmaceuticals
ACHN
$15.9M 1.22%
+4,296,000
New +$14.1M
HAPN
34
Happen Inc
HAPN
$2.02B
$15.1M 1.15%
+860,000
New +$16.6M
PRKS icon
35
CALL
United Parks & Resorts
PRKS
$1.83B
$14.8M 1.13%
+1,000,000
New +$14.7M
AVDL
36
DELISTED
Avadel Pharmaceuticals
AVDL
$13.4M 1.02%
1,836,000
+148,000
+9% +$1.3M
ONCE
37
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$12M 0.92%
+180,000
New +$10.4M
MDGL icon
38
Madrigal Pharmaceuticals
MDGL
$12.4B
$11.9M 0.91%
102,000
+42,000
+70% +$5.18M
AVXS
39
DELISTED
AveXis, Inc. Common Stock
AVXS
$10.9M 0.83%
+88,000
New +$10.5M
ENTA icon
40
Enanta Pharmaceuticals
ENTA
$395M
$10.7M 0.82%
132,000
+44,000
+50% +$3.39M
BLUE
41
DELISTED
bluebird bio
BLUE
$10.2M 0.78%
4,632
+1,930
+71% +$4.91M
ISEE
42
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.84M 0.75%
3,592,000
+142,000
+4% +$412K
ATEC icon
43
Alphatec Holdings
ATEC
$1.42B
$8M 0.61%
2,492,414
+1,714,000
+220% +$5.57M
APRN
44
DELISTED
Blue Apron Holdings, Inc. Class A Common Stock
APRN
$7.89M 0.6%
21,913
+16,357
+294% +$8.62M
PRTK
45
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$7.54M 0.58%
+580,000
New +$8.64M
AMZN icon
46
Amazon
AMZN
$2.77T
$7.24M 0.55%
100,000
– –
ALIM
47
DELISTED
Alimera Sciences
ALIM
$7.14M 0.55%
462,400
+8,267
+2% +$147K
LRMR icon
48
Larimar Therapeutics
LRMR
$416M
$6.71M 0.51%
75,000
-3,000
-4% -$254K
NVLN
49
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$6.5M 0.5%
1,856,000
– –
ASMB icon
50
Assembly Biosciences
ASMB
$718M
$6.29M 0.48%
10,667
+1,334
+14% +$827K
1
2
3 4

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Armistice Capital held 87 positions worth $1.31B, up 30% from $1B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Armistice Capital deployed $326M of net new capital in Q1 2018, opening 20 new positions and adding to 35 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 108,000 shares worth $37.2M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 34% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was Vanda Pharmaceuticals, an estimated $1.31M trimmed.

  • Armistice Capital's largest Q1 2018 buy was Regeneron Pharmaceuticals: 108,000 shares worth $37.2M.
  • Armistice Capital added most to United Therapeutics in Q1 2018, an estimated $23.9M increase.
  • Armistice Capital's biggest Q1 2018 reduction was Vanda Pharmaceuticals, cutting an estimated $1.31M.
  • Armistice Capital fully exited Energizer in Q1 2018, selling an estimated $29.4M.
  • Armistice Capital's ten largest holdings make up 40% of its $1.31B portfolio in Q1 2018.
  • Armistice Capital opened 20 new positions and closed 23 in Q1 2018.
  • Armistice Capital's portfolio value rose 30% quarter-over-quarter to $1.31B.

Based on Armistice Capital's 13F filing for Q1 2018, filed 15 May 2018.